Vir Biotechnology, Inc.
In the published model solve dated 2026-Q2, anchored at $9.13, Vir Biotechnology, Inc. (VIR) is priced for today's economics sustained for ~9.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Vir is a clinical-stage biotech, not yet a commercial one: it has negligible product revenue and its value rests on a pipeline led by tobevibart plus elebsiran for chronic hepatitis delta, where updated Phase 2 data showed 88% of evaluable patients reached undetectable virus at 96 weeks [Source: SOLSTICE Phase 2 update, 2026]. • The defining risk is the binary nature of drug development: the company posted a first-quarter net loss of $125.7 million on a cash-burning model, and its filing warns
Is VIR overvalued? See what's priced in →
241 institutional managers reported holding VIR in 13F filings for the quarter ended 2026-03-31. Together they hold about 94% of the company; the top 10 hold 57%. 59 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 18.1M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (11.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
VIR's share count grew 13.2% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at VIR over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
VIR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -3.0% | -35.0% |
| 2023-11-04 | +7.0% | +14.5% |
| 2024-02-27 | +14.1% | -26.0% |
| 2024-05-04 | +18.9% | -17.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
VIR's latest 8-K filings: 2026-08-05 (items 2.02, 9.01); 2026-07-24 (items 5.02); 2026-06-10 (items 5.02); 2026-05-28 (items 5.02, 5.07); 2026-05-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.